{"ticker": {"uuid": "5d8adb4b-b9f3-41c7-bbb7-96d6cd08a6f0", "symbol": "AORT", "name": "Artivion Inc", "exchange": "NYSE", "country": "US", "sector": "Healthcare", "industry": "Medical Devices"}, "articles": [{"title": "Artivion (AORT) Corporate presentation Summary", "summary": "Artivion (AORT) presented a summary of its financial performance, growth strategies, and product innovation, highlighting its specialization in aortic disease. The company reported FY25 revenue of $444 million and projected FY26 revenue of $480\u2013496 million, with strong EBITDA gro", "url": "https://quartr.com/events/artivion-inc-aort-corporate-presentation_ofoTIIV7", "source_name": "Quartr", "published_at": "2026-07-16T03:40:05", "published_display": "16 Jul 2026 03:40", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Reflecting On Medical Devices & Supplies - Specialty Stocks\u2019 Q1 Earnings: Integer Holdings (NYSE:ITGR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNUFd1SUpRcWlCdEFjU1YzNTZkdjBfRkwyY2lBYjh1ZXZlZTlyVlpWSWx1bExvckFrNHNhUEdVTGNFWUxaMkVDZUV2c2hPS1h2YVhNSHNsVzFYNUFrNHBnRVM1STRsa2Zmb0VXeEQ4UFRGNDBOWXZfWVU5VFUyQ3JZZm9KamZMWXVDSEtNMWwyVktpaEZfRjVNU1BYaWJ3NnpNUmRyMEpsSzBXdw?oc=5", "source_name": "Market source", "published_at": "2026-07-14T18:07:11+00:00", "published_display": "14 Jul 2026 18:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Artivion (AORT) Stock Forum and Discussion", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAJBVV95cUxOMGo5bUVjSnBOZGJseE9vUW9JOE1na1F4S2tVU1Z2R1dGTzF4Y0V1T0RjSmtyUXRkWUFOaTZ5UUFWVVA1eE04OEFwc2RZMm12VVFadTNHdGo5RTctMVMyQnhSalFhVUc2ZTg5dmZNcTdsN242MXhXQ3JqLVY4WnYtUGNzR24wYUZJbThkYXFwWGgyd0drZnZmckhZSTVfOF9lWkFSTkVDTFNOQ1lacFFHSEpaOVlrc3lyNFQxa2FDM1k2TDNEbkIwMWZnZDhaaktmb2QxaTJza1hOVC01bGRZakoxb244bWN1Y0NmV1I1S2lMWEJCbl94bm1MdzVXcXllLVBoUjdDNXJqNW4tVHR5VWE1VWtnUjFzM0ZZejRyaWxCN2Ff?oc=5", "source_name": "Moomoo", "published_at": "2026-07-09T12:46:52+00:00", "published_display": "09 Jul 2026 12:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artivion (AORT) Is Up 10.1% After Full FDA PMA Approval for AMDS Aortic Device", "summary": "Artivion (AORT) received full U.S. FDA premarket approval for its AMDS Hybrid Prosthesis, opening up a potential $150 million annual market and strengthening its growth prospects. Despite this positive clinical development, the company's recent removal from Russell indices could ", "url": "https://simplywall.st/stocks/us/healthcare/nyse-aort/artivion/news/artivion-aort-is-up-101-after-full-fda-pma-approval-for-amds/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-07T11:11:00", "published_display": "07 Jul 2026 11:11", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Boosted Artivion (NYSE:AORT) Following FDA PMA Approval?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOMVpJbzFidmJzZXpDODVKRERuNjNOU3ZjN1RIc2F0T3hXQzlvNWw2MXdPTjRJOWJVb2phWFV3dXNIbHVwemFmQ0w1SmlJOG5QYzAtY1VXYWNsVUdpWGpJaHo2eWRRU0FnX2trd3l6LUZHaGZEZUNiZ2dmZm1tekdzNm9QQWt4d28yWHNQdEJKd1NWUEVwX3NwLVJjam56cDFXRTh0MklB?oc=5", "source_name": "Kalkine Media", "published_at": "2026-07-07T05:12:00+00:00", "published_display": "07 Jul 2026 05:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artivion (AORT) Wins FDA Approval, Is The Stock Still 53% Undervalued?", "summary": "Artivion (AORT) recently received FDA premarket approval for its AMDS Hybrid Prosthesis, a move that has drawn significant attention to the stock. Despite a 19.14% increase in the last 30 days, the share price is still down 46.09% year-to-date and trades significantly below its U", "url": "https://simplywall.st/stocks/us/healthcare/nyse-aort/artivion/news/artivion-aort-wins-fda-approval-is-the-stock-still-53-underv/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-05T22:40:23", "published_display": "05 Jul 2026 22:40", "sentiment": "positive", "sentiment_pct": 76, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artivion\u2019s AMDS gets FDA approval for deadly aortic tears", "summary": "Artivion (NYSE: AORT) recently received U.S. FDA PMA approval for its AMDS Hybrid Prosthesis, designed to treat acute DeBakey Type I aortic dissections with malperfusion, a condition affecting approximately 60% of such cases. This approval eliminates the need for Institutional Re", "url": "https://www.stocktitan.net/news/AORT/artivion-announces-u-s-fda-approval-of-the-amds-hybrid-ttni6d66857b.html", "source_name": "Stock Titan", "published_at": "2026-07-03T11:12:51", "published_display": "03 Jul 2026 11:12", "sentiment": "positive", "sentiment_pct": 70, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artivion raises 2025 revenue guidance to $435M\u2013$443M as On-X and stent grafts drive double-digit growth", "summary": "Artivion has increased its 2025 revenue guidance to $435 million\u2013$443 million, driven by strong double-digit growth in its On-X heart valve and stent graft product lines. The company also reported Q4 2023 revenue of $85.6 million and full-year 2023 revenue of $334.2 million, surp", "url": "http://www.msn.com/en-us/money/other/artivion-raises-2025-revenue-guidance-to-435m-443m-as-on-x-and-stent-grafts-drive-double-digit-growth/ar-AA1Kb1AI?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-07-02T20:10:04", "published_display": "02 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artivion Secures FDA Approval for AMDS Hybrid Prosthesis Device", "summary": "Artivion has received FDA premarket approval for its AMDS Hybrid Prosthesis, designed to treat acute DeBakey Type I aortic dissections. This approval removes the previous requirement for institutional review board oversight, which is expected to broaden adoption across U.S. hospi", "url": "https://finance.yahoo.com/healthcare/articles/artivion-secures-fda-approval-amds-141200437.html", "source_name": "Market source", "published_at": "2026-07-01T14:40:02", "published_display": "01 Jul 2026 14:40", "sentiment": "positive", "sentiment_pct": 76, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artivion announces US FDA approval of AMDS hybrid prosthesis", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxOMjR2TmhXMnhPakJ4b1ZlSW5zVElKSnI1LXJlbFJOWU5CVEt1R0NVSWNBRk1qakhDeW1PV0tsM3h4b0ZOOTVPek9NVlNYU2lQUFljem9OREMxLWQ1dnIzR0Izb1diMU9VVjRCR0pRWW8tZWpydkZmUXhyZHJtSEdadDhHWHdVZGJVTVZTYWlTVQ?oc=5", "source_name": "Vascular News", "published_at": "2026-06-30T10:01:38+00:00", "published_display": "30 Jun 2026 10:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artivion's Hybrid Prosthesis Device Gets FDA Premarket Approval; Shares Up Pre-Bell", "summary": "Artivion (AORT) announced that its AMDS hybrid prosthesis device has received U.S. Food and Drug Administration (FDA) premarket approval. The device is designed to treat thoracoabdominal aortic aneurysm (TAAA) disease. Following the announcement, shares of Artivion were up over 7", "url": "https://www.moomoo.com/news/post/72189692/artivion-s-hybrid-prosthesis-device-gets-fda-premarket-approval-shares?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-06-30T08:40:52", "published_display": "30 Jun 2026 08:40", "sentiment": "positive", "sentiment_pct": 82, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artivion: PMA Approval Supports Accelerating Growth And Margin Expansion (NYSE:AORT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOVk04WEpqMEVnYVNtblZZWmlnbDNmVHRhV1BjS01KUEJaUEtybWI4ZUpwSmJ2WVBpNDUtN2tPTXZJdjRxYUpmQUd4RHVieTBiUG1mOTRpdzU1WmxFMDlPVHJVcG5tcWdGZzZRMnhhY3hWaDFDeE9hSjN3MVZBMEFFQk9oVmwta3gxN0EzZnZlcDBFU2hVajZCNjdraVM5aTg0QjVpY1hDVzRvQllBZlFkeDU2Ym45bHVaNmc?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 95, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Artivion, Inc. \u2013 SWB:CYL", "summary": "This article provides financial information for Artivion, Inc. (SWB:CYL) on the Stuttgart Stock Exchange. It specifically highlights the enterprise value to revenue forward metric for the company. The content appears to be a financial data point or a brief note from a financial p", "url": "https://www.tradingview.com/symbols/SWB-CYL/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T00:09:48", "published_display": "30 Jun 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artivion Seeks To Tap $150 Million US Market Opportunity With FDA Approval", "summary": "Artivion Inc. received FDA approval for its AMDS Hybrid Prosthesis, which treats acute DeBakey Type I aortic dissections, removing previous institutional review board requirements and easing access for hospitals. This approval validates clinical benefits observed in the PERSEVERE", "url": "https://www.sahmcapital.com/news/content/artivion-seeks-to-tap-150-million-us-market-opportunity-with-fda-approval-2026-06-29", "source_name": "Sahm", "published_at": "2026-06-29T21:41:47", "published_display": "29 Jun 2026 21:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AORT - Artivion Inc Options", "summary": "This article provides an overview of Artivion Inc. (AORT) stock options, displaying key financial metrics and performance indicators as of June 30, 2026. It includes data on market capitalization, earnings, sales, insider and institutional ownership, and various price performance", "url": "https://finviz.com/stock?t=AORT&ta=1&p=m&ty=oc&b=2&r=y5&ov=list_strike&s=12.5", "source_name": "Finviz", "published_at": "2026-06-29T20:10:13", "published_display": "29 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Artivion (AORT) Is Up 17.3% After Full FDA PMA Approval for AMDS Hybrid Prosthesis", "summary": "Artivion (AORT) shares rose 17.3% after receiving full FDA premarket approval for its AMDS Hybrid Prosthesis for acute DeBakey Type I aortic dissections, eliminating the need for prior hospital IRB approval. This approval validates the device's trial data, which showed significan", "url": "https://simplywall.st/stocks/us/healthcare/nyse-aort/artivion/news/why-artivion-aort-is-up-173-after-full-fda-pma-approval-for", "source_name": "Simply Wall Street", "published_at": "2026-06-29T17:40:53", "published_display": "29 Jun 2026 17:40", "sentiment": "positive", "sentiment_pct": 81, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artivion Wins FDA Nod for AMDS Hybrid Prosthesis", "summary": "Artivion has received U.S. FDA approval for its AMDS Hybrid Prosthesis, designed to treat acute DeBakey Type I aortic dissections. This device is the first aortic arch remodeling device for this condition and has shown significant reductions in mortality and major adverse events ", "url": "https://www.mpo-mag.com/breaking-news/artivion-wins-fda-nod-for-amds-hybrid-prosthesis/", "source_name": "Medical Product Outsourcing", "published_at": "2026-06-29T14:40:53", "published_display": "29 Jun 2026 14:40", "sentiment": "positive", "sentiment_pct": 95, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artivion Shares Rise After FDA Approves AMDS Aortic Device", "summary": "Artivion Inc. (NYSE: AORT) saw its shares rise after the FDA approved its AMDS Hybrid Prosthesis for treating acute DeBakey Type I aortic dissections, particularly those involving malperfusion. This approval removes the need for institutional review board authorization, broadenin", "url": "https://www.tradingpedia.com/2026/06/29/artivion-shares-rise-after-fda-approves-amds-aortic-device/", "source_name": "TradingPedia", "published_at": "2026-06-29T14:40:53", "published_display": "29 Jun 2026 14:40", "sentiment": "positive", "sentiment_pct": 87, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artivion, Inc.(NYSE: AORT) dropped from Russell Microcap Value Benchmark Index", "summary": "Artivion, Inc. (NYSE: AORT), a medical device company specializing in aortic diseases, has been removed from the Russell Microcap Value Benchmark Index. This news follows several other recent index removals for Artivion from benchmarks such as the Russell 2000 Defensive Index, Ru", "url": "https://www.marketscreener.com/news/artivion-inc-nyse-aort-dropped-from-russell-microcap-value-benchmark-index-ce7f5fded08cfe25", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T12:40:53", "published_display": "29 Jun 2026 12:40", "sentiment": "negative", "sentiment_pct": 27, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artivion receives FDA PMA approval for AMDS Hybrid Prosthesis in aortic dissections", "summary": "Artivion (NYSE:AORT) has received U.S. FDA premarket approval for its AMDS Hybrid Prosthesis, designed to treat acute DeBakey Type I aortic dissections with malperfusion. This approval eliminates HDE-related institutional review board requirements and is supported by data from th", "url": "https://grafa.com/en/news/united-states/artivion-fda-pma-approval-amds-hybrid-prosthesis-aortic-dissection", "source_name": "grafa.com", "published_at": "2026-06-29T11:59:00", "published_display": "29 Jun 2026 11:59", "sentiment": "positive", "sentiment_pct": 91, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artivion Announces U.S. FDA Approval of the AMDS Hybrid Prosthesis", "summary": "Artivion, Inc. announced that the U.S. FDA has approved the premarket approval application (PMA) for its AMDS Hybrid Prosthesis, a device for treating acute DeBakey Type I aortic dissections. This approval removes the previous requirement for hospitals to obtain IRB approval, fac", "url": "https://www.prnewswire.com/news-releases/artivion-announces-us-fda-approval-of-the-amds-hybrid-prosthesis-302812309.html", "source_name": "PR Newswire", "published_at": "2026-06-29T10:40:53", "published_display": "29 Jun 2026 10:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artivion receives FDA approval for aortic dissection device", "summary": "Artivion, Inc. (NYSE: AORT) has received FDA approval for its AMDS Hybrid Prosthesis, a device designed to treat acute DeBakey Type I aortic dissections, particularly those with clinical or radiographic malperfusion. This approval, based on positive data from the PERSEVERE U.S. I", "url": "https://www.investing.com/news/company-news/artivion-receives-fda-approval-for-aortic-dissection-device-93CH-4764985", "source_name": "Investing.com", "published_at": "2026-06-29T07:20:00", "published_display": "29 Jun 2026 07:20", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Artivion, Inc. \u2013 NYSE:AORT", "summary": "This page provides financial data for Artivion, Inc. (NYSE: AORT), specifically focusing on its forward price-to-earnings ratio. The content is presented within the TradingView platform, offering an overview of the company's financials for investors and traders.", "url": "https://www.tradingview.com/symbols/NYSE-AORT/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T20:40:08", "published_display": "28 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artivion, Inc. Actuals & Estimates (NYSE:AORT)", "summary": "This article provides an overview of Artivion, Inc. (AORT) stock, including its current price, market capitalization, and historical performance. It also details analyst forecasts, upcoming earnings reports, and financial metrics such as revenue, net income, and EBITDA, while cla", "url": "https://www.tradingview.com/symbols/NYSE-AORT/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T05:10:02", "published_display": "26 Jun 2026 05:10", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AORT Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Artivion, Inc. (AORT) stock, including analyst price targets, historical performance, and key financial metrics. According to 8 analysts, AORT has a max price estimate of $48.00 and a min estimate of $36.00. The article also details the compan", "url": "https://www.tradingview.com/symbols/NYSE-AORT/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T19:10:40", "published_display": "25 Jun 2026 19:10", "sentiment": "positive", "sentiment_pct": 59, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artivion Inc (AORT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a detailed revenue breakdown for Artivion Inc (AORT), showing its performance by business segment and geographical region. As of the latest update (Mon, Apr 6), the company's major revenue contributors are Aortic stent grafts, On X, and Preservation Services", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-aort/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T09:40:31", "published_display": "18 Jun 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artivion\u2019s Andrew Green sells $910,738 in company stock", "summary": "Andrew M. Green, SVP of Regulatory and Quality at Artivion (NASDAQ:AORT), sold company common stock totaling $910,738 on June 11, 2026. These transactions, executed under a Rule 10b5-1 trading plan, involved 44,001 shares at weighted average prices between $20.694 and $20.707. Pr", "url": "https://www.investing.com/news/insider-trading-news/artivions-andrew-green-sells-910738-in-company-stock-93CH-4742703", "source_name": "Investing.com", "published_at": "2026-06-16T14:40:31", "published_display": "16 Jun 2026 14:40", "sentiment": "negative", "sentiment_pct": 41, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artivion\u2019s Andrew Green sells $910,738 in company stock By Investing.com", "summary": "Andrew M. Green, SVP of Regulatory and Quality at Artivion (NASDAQ:AORT), sold 44,001 shares of company stock for $910,738 on June 11, 2026, under a Rule 10b5-1 trading plan. This sale occurred after he acquired the same number of shares through stock option exercises for $589,07", "url": "https://m.in.investing.com/news/insider-trading-news/artivions-andrew-green-sells-910738-in-company-stock-93CH-5455231?ampMode=1", "source_name": "Investing.com India", "published_at": "2026-06-15T16:40:12", "published_display": "15 Jun 2026 16:40", "sentiment": "negative", "sentiment_pct": 40, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artivion Insider Sold Shares Worth $910,739, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/artivion-insider-sold-shares-worth-153637872.html", "source_name": "MT Newswires", "published_at": "2026-06-15T15:36:37+00:00", "published_display": "15 Jun 2026 15:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artivion (AORT) SVP exercises options and sells 44,001 shares under 10b5-1 plan", "summary": "Artivion, Inc. (AORT) Senior Vice President Andrew M. Green executed a pre-arranged transaction under a Rule 10b5-1 trading plan, exercising stock options for 44,001 shares and subsequently selling all of these shares in open-market transactions. The sales occurred on June 11, 20", "url": "https://www.stocktitan.net/sec-filings/AORT/form-4-artivion-inc-insider-trading-activity-b328cd4db715.html", "source_name": "Stock Titan", "published_at": "2026-06-15T15:40:11", "published_display": "15 Jun 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks Q1 Earnings: ICU Medical (NASDAQ:ICUI) Firing on All Cylinders", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAJBVV95cUxQLWl0NWl5MFJhUXFSN0pzSW1sVzJVb21XVml0X0doQnd5eDVUQmVqeFZWSmNmdlZaV2pfbFk3UEl3RXlqZ05pckozR0dnNHNEUlpTa2FPYWc1Z3Q0Y2tXYTljZUlQRkVZNzY2Sl9yRksyUDJkNVQzSTBuLW9uMnI5bzBfTTJGdDUzd25DN3dDSmhwWnpGVXZRVVM2Uy1zMnp4STZ1RGdZZkRpZ21Pb2xtWjRSTk1kc2JrT28wTG81NDV1M2tWaVdrOXBQdVZSTExiTVEzMXpqRnJWWi0xcEdMYVFILXZXbXZVZl9GRm12aTl5OGk4X1dSVjVyU2FIVFpubk1YNm5fQll0MVZqRTZpTA?oc=5", "source_name": "StockStory", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Precision Trading with Artivion Inc Com (AORT) Risk Zones", "summary": "This article analyzes Artivion Inc Com (AORT) with a focus on risk zones and trading strategies developed by AI models. It identifies a near-term neutral sentiment but suggests weakness in the mid and long term, highlighting elevated downside risk. The article provides specific s", "url": "https://news.stocktradersdaily.com/news_release/1/Precision_Trading_with_Artivion_Inc_Com_AORT_Risk_Zones_061326063202_1781389922.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-13T18:32:00", "published_display": "13 Jun 2026 18:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Artivion (AORT)'s Strong Q1 Growth But Lowered Guidance Means For Shareholders", "summary": "Artivion (AORT) reported strong 17.5% year-over-year revenue growth in Q1 2026 to US$116.3 million but missed analyst EPS estimates and slightly reduced its full-year guidance. This mixed performance highlights the company's growth momentum alongside challenges in profitability a", "url": "https://finance.yahoo.com/markets/stocks/articles/artivion-aort-strong-q1-growth-081650954.html", "source_name": "Market source", "published_at": "2026-06-12T08:10:28", "published_display": "12 Jun 2026 08:10", "sentiment": "negative", "sentiment_pct": 41, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] ARTIVION, INC. SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxQS0pKT2h4U3JZQ1RrblJiS01NbG53elFOY0xSNlMwQXc3VFBaRDMyOXZpT3VTQThVWlM1bUo0Skd6akdvVUZYbWhhUXpGaXZPV1gxdWltV3paS2xxazVQN2ZjeFF4aHZaTUtrWmcxTXczaEdKLWdmYjZoUW5XdGtaaHd2aWJYdW03WlJHWlNFVDY0cDg?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artivion (AORT) Q1 2026 Earnings: Revenue Growth of 17.5% Meets Expectations Amid Mixed Industry Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxPNVFJS3lud1FKdVE1UXdhNjNzQUM1OTgxZGtpYjFCaG43Zk5TOFUxU1AxalFmZHZHUmk5TUpwbnEzdndwYmstRU9yVXZCRjBkVXNWdXZjaXpwbjRJQ1dwNkNwZC01VFBja1R0RkJlQlZ4N2N0dTltUDMtUlJMWjBHd0FLUmpOcXpWS3gyVEFNUEt6ZzB5QU13SF8wWnZJLTZRem1SdXdBWlFpM01IZTNuZWtVcDhDeWNIN2RYajVJdmdsRmMtaGFqYg?oc=5", "source_name": "IndexBox", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Outperformers: Artivion (NYSE:AORT) And The Rest Of The Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQWlEweko5d2hyZUFhUjRsYU1QcElacmR0UktDcFZGUmFXSHpGN05OLV9tYS1VRTlfTHpGRXEzNi12cXZlcTJYVDhZRTZnWG1DUEVFT3hxMG5RcUpORUsyQWN3VVY0eENoZnFMYkdLOXk1Y2d5SFluWDBZU2ZsUl90cHZWY2pKQXZwS212WkcxejJjQ3hlYmtqMFRhWm1neHVYRDZvUzFtVmM4dXVY?oc=5", "source_name": "Market source", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Review: Medical Devices & Supplies - Diversified Stocks Led by Baxter (NYSE:BAX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNYjhBT3BjMWFVU1FFUUFub0d6QUVEUTdwWFVMRG5fN2dHSnIxTXQwMWU1aElKaEV1a2dYLTFHMlBzMVFTZEtaX0xRRDFhZDl1WFdDYWF2RDZxOG9SRUtycmZacTRzM2FaaEU3OS1GZ2taLWtSMjZ4enhVNHRvdzJsanp4cEhNcGI1dllTOUplWUUtNjRlRm85MlFEVWxSYUV2d243QVd3?oc=5", "source_name": "Market source", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Artivion (NYSE:AORT) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxQcFVzS0xkWUdmUDQydWdoT2U2aF9DRkR0LUtWajA1MUZyMVlTbEJBR0h0S0FTN1ozY3k1SnlhMXB6WTZNRU95NVpScHNCVE5PRDRhX1IxcTFBenI1ZDdtRkdlN0t5azQ3eE1KLWYyWExfenF6TVN5bjBWUFFwUU1aczJvRk9mUDBzSjZEa1dlMW9VVUxQMFdxSGxZdHp1SHc?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artivion to acquire Israeli medtech firm Endospan in deal worth up to $335 million", "summary": "", "url": "https://news.google.com/rss/articles/CBMiaEFVX3lxTFB2M0NPTTV0WVhBeVR1MmZCT3dyVl81aHF5ZHZIMkRyV05pV3hCc0VwNkgtaEcxa2lmZWlJUzFyTS00NHhQZ0RSNXFIaXFtVGg0Uk5pZmRPNFZrMGE0cWdTZUhmaUw5VnJr?oc=5", "source_name": "calcalistech.com", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artivion Stock Dips 28% In One Day, Now Is Not The Time To Buy The Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxOZDdPZHJ3SUNQTzJvbUtuYUpZVHJMaHdHN3I2UVhFakYxTGt1UmxXcDlVUDNJckNubHhFRmVkT09fbTk3LWVhOUNsRDdBWHJYOWtvMHU0TE81ck5ISlIxcGZ4RFduOWZ6d191WmYyRHEwTmZYcnBMb2hvcTdHd09WR2hZVnUyb3BwZVphWkswWi05ZjVzMDNISXI0TDJqTDZyLUF4d2RFYmxIQ2tRM0k1N0x6WEY4Nk50cjU5bm5oNDd3aTFSbUpzYkNmZnAwX3RoM2VlVGw3Zw?oc=5", "source_name": "Trefis", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is Artivion stock plummeting today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOb3Y4ckVPVjFBXzZUNTJ4Nkt2LVVVY1ZKSUo1cF96UlhzaG1Gc2pydHYxY3lDajdOY25kMUFyb0EzbnhfNkVQXzNhWEg1NVA1cmVodlR5aUstTUxaX0V0OFR6amJ1NHRUWVZGNmYxb0t4cUh4YzUweV9zalBYckxZcnNOTTY1cHpvczlEWUYyTWNiRkVQYjJVUWNVVjNjQ1Z3UXc?oc=5", "source_name": "Investing.com", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Artivion (AORT) Stock Is Falling Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNQXRXbmhpcTJZZDNFSEo0WU9rNmhWcWdaTEZxYlpVRlNicmhvOFEzU3pwWC1rbHNFVWNJUDZuYnpzN0pwNVREVEFNSndaWWJoRGhRNW44UTA4M05rNHBZeHUtM0lKMkJvTm96TnNTR3RYa3lOWWNvQllSTzliYlZyNHlpal9KZ2ItMFJ5aWc5aDZ3NFVFbnJkVllIdUFVTUNFQkE?oc=5", "source_name": "StockStory", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artivion Reports First Quarter 2026 Financial Results and Announces Exercise of Option to Acquire Endospan", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9AFBVV95cUxPR3NQT00xOU91TkJWRktPVUZOYlQxV1FwclVJVEl0cWRDRU9TUHl4WmJsNEJheUdfWkY4U3k2NW5NSjktdURYamRTYk1HNzlaX0RTYy1YeUcxNU9EYkRBT3QtT0RWVmJPWi1NVWExMDF2bVhZbnN2T1Z3cXdvczFkNUJOTUNvRmQ2WFVIVGtGMEdNT2Q2aGVjN1ZuSGNhUGpfR0VuVzkwMGtWeEhFLTd6S3RJSUlkbER2aVlsRlJTcDB1c3pJeThrNVc0My1uRXNtdVo4YkFhYldJWUxvU1VPckpXZXRZMldPNlJhNmxtM1lPcDRB?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artivion (AORT) Q1 Earnings and Revenues Surpass Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQVU9JNFVrOUo0T1N1NEV2VHFSNm5IeFEyU1Z4aUdzNS1CbFE4TnVzX0k0US1ReDFWeE1qejlVcUFCcU9pVEJGWjI1aUFtdVMtb3FvLTZ6Y2M5Z01Sd1N1VTExRlN3VEZjbjBLTjZDekdHRUxIM2tRbnktNF9fQlR0TTdrQ2JLZjM2djdPN1d5ci1Jd3RObURmSlhrSEVIOFRr?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Medical Devices & Supplies - Specialty Q4 Earnings: Globus Medical (NYSE:GMED) is the Best in the Biz", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNcDFMNmtOVk5PVFM1YzMyVWhyS3dwY0dMVE5BUng5U1JoOFRQMXNFRGxTMmlBRUV0bENRSWFXTDFZOXBQQkNZT0FOWDdISjRCcU9pRV9aNHBwUVBuZkVEV3g1dklVY19KOE9iWUNpNUtMS2NuOEcxMlQtNU8ydURybEdkNVoxZThWLTBIeVhid2NjQ0FWWTUzb2dxcmlMQThFQmZ4bldzRjcwUQ?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Artivion (AORT) Soars 5.3%: Is Further Upside Left in the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxOelZodXlrMW5BMXZZNDdVenE1RE14Wlp0QUdWM3p0MWU3c1FDRXE3RjZnemhWaDhKWUV3WC1jMnFJbUdSQjVzX1lWc0ppc2xWMVNRWTNQRmFRVUhROGN1NkdFQTFscmV0RlpVeHBHWlRub1lGenFsMHRpRWFPa09nY1FTLUJWWFFOT0E5T3RnU1NuZw?oc=5", "source_name": "Market source", "published_at": "2026-04-08T07:00:00+00:00", "published_display": "08 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artivion Announces U.S. FDA Approval of the NEXUS\u00ae Aortic Arch System", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOUF9CTFg1VUo4R0E3UFBockdCZWI0Qi1XWF9vV2p5YVktanRRSU1TazlBdFhPSzFKbjFYTVZqNUk3a29OdGpkTm1xY0toU0x6TTUyZjMtSkZnTU51N1ZUOXdoNnNEbl8tQW1neG5TZnlKT3hGTE05WnJVSDJuSXp2dWFickl4MkxZMm9ZUDR0bXBLU1NxZHJsWFN6OXhIWDEzcG1VbnRWNmIwQnJrRG1zSVYxbV9YV1FIeFNwNmZobw?oc=5", "source_name": "PR Newswire", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Medical Devices & Supplies - Imaging, Diagnostics Stocks\u2019 Q4 Earnings: Hologic (NASDAQ:HOLX) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOdkl6Ym5HSGVhZUw3TzNlNVFPSjdDQk5NMTVSRW1xVnh3RE5RNU9veVR0TDEtcVdxV3BYelI0bWxCYXgwWmhZQ3ZONUVRdlhjX0ZiMklRVDJQRXN0LXcyVWVnb0E2WTdiRERtZk1pNGpmVHhWbHl5eHJuNnBtTDVPMUluTmRsQUVqYjNlSl8zR3djclh0X2ZIc1gzTlhPanR6ZTJ6R1FB?oc=5", "source_name": "Market source", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Why Artivion (AORT) Stock Is Down Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxOZk9qVWoxaWFWT0daTkVOSEhyNVhrTnFyYmJPZ1RLU2FoNGl5RS1FazNQeVlnNDFlTS1mUVpBUWwwcGRManRDNWd5MmhoSFp4RWM5bGVMdHF6dkRSREo2d0cxR05JZUg1T21BZDF5Vzh6S1JFaTg4SWVTZDJHTmJxUXdVcmIxczhvSDlRUkYxdHhkRDlBeVpieQ?oc=5", "source_name": "Market source", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Artivion (NYSE:AORT) Vs The Rest Of The Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPaTgxS3dlMlZ5dDZ3dFlGdG9yRWFubkVqMk9yOTN6OEtyemljTWJGYUcxb2pmd2FTNTFKMlhIVGxrdlJsOG5iY1VQaXE4ZmYycTVpRkE0aEJ3QlB5bC10ZXN2dTFYNy0wRWdrNURVUlo5dEMzQklxQ0kwQTRkOXE0UDdTMkRGRWxoQ1ZQeG4tOXNONlR2SkxfZW5ST1B6N3BBeFZZQ3N1UFE?oc=5", "source_name": "Market source", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: CooperCompanies (NASDAQ:COO) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOellVLTAtRXF1dTFacmVLUmptUVpDSkxGX0MtY2hCY2l3ajU4M25SMG95OHdlc1RHN1dmaHZZMF9uQ0o3R1FBa0NzQUtZMjIzMjU1bmttbGZsZUplQkd5Vmd2NEJoQ0NnbVhmVXppdWhiQkdpcGpQVFJVSHRBXy1pbnFJbXI0R2w3MmlvMEdCY2dGYVE4cWY2MENmeEp1ME9mZEFqSDVtdThTMk9kbUhIdXMtR0k?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q4 Earnings: Integer Holdings (NYSE:ITGR) In The Context Of Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAJBVV95cUxNdFRrRlJvM3J3cGJnVEJ6ZndqMnQxWkE4Wm8zTGtPTVc0OTlLN1pwNXIyclNJMFZkcG5qQTRTWThmNm9WN0hKYXBja3N3Y20zSlkxc2JaQlpYTnAyWnpvUVBvR1JWNmVxZGhSYVlYQklMd01GeFBVNGJWOFBWYUkwYmRrM2xrSktiQWpfTkZtNG1HWThNT0tqLUpYek5qcnFWMGE0QV9CaElrMUpfTEhnOC1pS2t1bkE2VVJHdEhWdEtoX2xKNE1MWk1OSlBSNTVZVU83WEpnb3E4aURwQ3ZyZUFDbndpTTZEa0lZRTJvU2VuTDhreXdCQ25iV3Y4YWxENm1xYQ?oc=5", "source_name": "StockStory", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highs And Lows: Abbott Laboratories (NYSE:ABT) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPeVpVN2I3X3lJNXd3TXJmRWV4X0RvRDdYR3l5a1k1SjMxUlhsWHdrUUNuZ1JIaUg4czdhZlA2VDVIallROFFuNmZXcnNzS1d3Vm0wS0tLMmlFVWdkUThsRDZYdTdZV3k3WkRjaUZSMUQ3dkRKYm5ZOVBjMVVBdTRjYQ?oc=5", "source_name": "Market source", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q4 Earnings: Enovis (NYSE:ENOV) In The Context Of Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNMzBPcXU1cnZKekZnaGlNVk05ZWFTWThNOS0tTlpvQjdaLVZIWlVXUk50NnVoQ0pPWWJpZUpWcVJyVDJMd2RJREVDbEEzTlU5UGhBbWtxWVEyVkdaMTVuNXZpaWFMNTZUQ2d0OW9Rc29kalJRY21naWlHZDBLS3RuZV9wdTdIUQ?oc=5", "source_name": "Market source", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highs And Lows: Baxter (NYSE:BAX) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxOb3BiQVNFREdNblk2QS10b1lhRUtfb05vU2VFZHB5V0hJT0R4NmhwQWRrcFVsR3UwMjZleFV6N2FEelpZVzY3YWFxSWE1cWpLaTFrQVU4NktkQUloUkxaV3ZTVkh6b1ZmaDdMN2ViX1BUNE4xUTNUZFNlR0syVGlZSg?oc=5", "source_name": "Market source", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "We Think Artivion's (NYSE:AORT) Profit Is Only A Baseline For What They Can Achieve", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-19T08:00:00+00:00", "published_display": "19 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Artivion (AORT) Is Down 7.6% After Mixed Q4 Results And 2026 Guidance Above Consensus", "summary": "", "url": "https://news.google.com/rss/articles/CBMiekFVX3lxTE1CR3J2NGNNTmRVRV9RRmFia1BiVjhKN2ZRcHNfakY0OXd2VldycVVlR2dGaDlmcTZfMUd5eVYwal81Wm01OWlOZEtGdU5SdHZMYVhfX0tRaG1YMHRGT2o2YVR4UTB5eWdtN0hNRG8zaGJIOUZKQXRmMjVR?oc=5", "source_name": "Market source", "published_at": "2026-02-13T08:00:00+00:00", "published_display": "13 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artivion (AORT) Stock Trades Down, Here Is Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxOUkF3ZmF5aWE2QXp5NXNBWUxILTROSnZadmVicDEybndvVHdkMkt1RWtQVVA5QU5XdVdxQW5yZ3JXeUQ4V3F5UHhPOFFKZGNPRGxSLXRBak93ZFpoLXd1cUhEdUxZVVA2UXRmWlgzWi1xVTFEME1uQVNHcllpcngzdk1Ddw?oc=5", "source_name": "Market source", "published_at": "2026-02-13T08:00:00+00:00", "published_display": "13 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artivion Reports Fourth Quarter and Full Year 2025 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxOczFDeHJMOU1jbFFTNXR1SE1lZmdrUU1PZ3BFUmFteFJFRng3RHAzMU5QS3ZWQzhLVklyVElpWlBqM1phVVNIMGhBRGtrMXRZUXJiNm1zNW15bVBwOXByc2ZydkZkUC1EQzE3eEJPUXBVTkY0YVFLb290eGoyWTZUX09UMnNsTUg2ZlJuUk13MVFhWDZPeDRKdWVEWXhyc3JoUVlfMFVSWU5yQmJpLThZY0ZqZFpFMDdIZXJyelFRWUdPQQ?oc=5", "source_name": "PR Newswire", "published_at": "2026-02-12T08:00:00+00:00", "published_display": "12 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Artivion (AORT) Corporate presentation Summary", "summary": "Artivion (AORT) presented a summary of its financial performance, growth strategies, and product innovation, highlighting its specialization in aortic disease. The company reported FY25 revenue of $444 million and projected FY26 revenue of $480\u2013496 million, with strong EBITDA gro", "url": "https://quartr.com/events/artivion-inc-aort-corporate-presentation_ofoTIIV7", "source_name": "Quartr", "published_at": "2026-07-16T03:40:05", "published_display": "16 Jul 2026 03:40", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artivion (AORT) Stock Forum and Discussion", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAJBVV95cUxOMGo5bUVjSnBOZGJseE9vUW9JOE1na1F4S2tVU1Z2R1dGTzF4Y0V1T0RjSmtyUXRkWUFOaTZ5UUFWVVA1eE04OEFwc2RZMm12VVFadTNHdGo5RTctMVMyQnhSalFhVUc2ZTg5dmZNcTdsN242MXhXQ3JqLVY4WnYtUGNzR24wYUZJbThkYXFwWGgyd0drZnZmckhZSTVfOF9lWkFSTkVDTFNOQ1lacFFHSEpaOVlrc3lyNFQxa2FDM1k2TDNEbkIwMWZnZDhaaktmb2QxaTJza1hOVC01bGRZakoxb244bWN1Y0NmV1I1S2lMWEJCbl94bm1MdzVXcXllLVBoUjdDNXJqNW4tVHR5VWE1VWtnUjFzM0ZZejRyaWxCN2Ff?oc=5", "source_name": "Moomoo", "published_at": "2026-07-09T12:46:52+00:00", "published_display": "09 Jul 2026 12:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artivion (AORT) Is Up 10.1% After Full FDA PMA Approval for AMDS Aortic Device", "summary": "Artivion (AORT) received full U.S. FDA premarket approval for its AMDS Hybrid Prosthesis, opening up a potential $150 million annual market and strengthening its growth prospects. Despite this positive clinical development, the company's recent removal from Russell indices could ", "url": "https://simplywall.st/stocks/us/healthcare/nyse-aort/artivion/news/artivion-aort-is-up-101-after-full-fda-pma-approval-for-amds/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-07T11:11:00", "published_display": "07 Jul 2026 11:11", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Boosted Artivion (NYSE:AORT) Following FDA PMA Approval?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOMVpJbzFidmJzZXpDODVKRERuNjNOU3ZjN1RIc2F0T3hXQzlvNWw2MXdPTjRJOWJVb2phWFV3dXNIbHVwemFmQ0w1SmlJOG5QYzAtY1VXYWNsVUdpWGpJaHo2eWRRU0FnX2trd3l6LUZHaGZEZUNiZ2dmZm1tekdzNm9QQWt4d28yWHNQdEJKd1NWUEVwX3NwLVJjam56cDFXRTh0MklB?oc=5", "source_name": "Kalkine Media", "published_at": "2026-07-07T05:12:00+00:00", "published_display": "07 Jul 2026 05:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artivion (AORT) Wins FDA Approval, Is The Stock Still 53% Undervalued?", "summary": "Artivion (AORT) recently received FDA premarket approval for its AMDS Hybrid Prosthesis, a move that has drawn significant attention to the stock. Despite a 19.14% increase in the last 30 days, the share price is still down 46.09% year-to-date and trades significantly below its U", "url": "https://simplywall.st/stocks/us/healthcare/nyse-aort/artivion/news/artivion-aort-wins-fda-approval-is-the-stock-still-53-underv/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-05T22:40:23", "published_display": "05 Jul 2026 22:40", "sentiment": "positive", "sentiment_pct": 76, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artivion\u2019s AMDS gets FDA approval for deadly aortic tears", "summary": "Artivion (NYSE: AORT) recently received U.S. FDA PMA approval for its AMDS Hybrid Prosthesis, designed to treat acute DeBakey Type I aortic dissections with malperfusion, a condition affecting approximately 60% of such cases. This approval eliminates the need for Institutional Re", "url": "https://www.stocktitan.net/news/AORT/artivion-announces-u-s-fda-approval-of-the-amds-hybrid-ttni6d66857b.html", "source_name": "Stock Titan", "published_at": "2026-07-03T11:12:51", "published_display": "03 Jul 2026 11:12", "sentiment": "positive", "sentiment_pct": 70, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artivion raises 2025 revenue guidance to $435M\u2013$443M as On-X and stent grafts drive double-digit growth", "summary": "Artivion has increased its 2025 revenue guidance to $435 million\u2013$443 million, driven by strong double-digit growth in its On-X heart valve and stent graft product lines. The company also reported Q4 2023 revenue of $85.6 million and full-year 2023 revenue of $334.2 million, surp", "url": "http://www.msn.com/en-us/money/other/artivion-raises-2025-revenue-guidance-to-435m-443m-as-on-x-and-stent-grafts-drive-double-digit-growth/ar-AA1Kb1AI?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-07-02T20:10:04", "published_display": "02 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artivion Secures FDA Approval for AMDS Hybrid Prosthesis Device", "summary": "Artivion has received FDA premarket approval for its AMDS Hybrid Prosthesis, designed to treat acute DeBakey Type I aortic dissections. This approval removes the previous requirement for institutional review board oversight, which is expected to broaden adoption across U.S. hospi", "url": "https://finance.yahoo.com/healthcare/articles/artivion-secures-fda-approval-amds-141200437.html", "source_name": "Market source", "published_at": "2026-07-01T14:40:02", "published_display": "01 Jul 2026 14:40", "sentiment": "positive", "sentiment_pct": 76, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artivion announces US FDA approval of AMDS hybrid prosthesis", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxOMjR2TmhXMnhPakJ4b1ZlSW5zVElKSnI1LXJlbFJOWU5CVEt1R0NVSWNBRk1qakhDeW1PV0tsM3h4b0ZOOTVPek9NVlNYU2lQUFljem9OREMxLWQ1dnIzR0Izb1diMU9VVjRCR0pRWW8tZWpydkZmUXhyZHJtSEdadDhHWHdVZGJVTVZTYWlTVQ?oc=5", "source_name": "Vascular News", "published_at": "2026-06-30T10:01:38+00:00", "published_display": "30 Jun 2026 10:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artivion's Hybrid Prosthesis Device Gets FDA Premarket Approval; Shares Up Pre-Bell", "summary": "Artivion (AORT) announced that its AMDS hybrid prosthesis device has received U.S. Food and Drug Administration (FDA) premarket approval. The device is designed to treat thoracoabdominal aortic aneurysm (TAAA) disease. Following the announcement, shares of Artivion were up over 7", "url": "https://www.moomoo.com/news/post/72189692/artivion-s-hybrid-prosthesis-device-gets-fda-premarket-approval-shares?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-06-30T08:40:52", "published_display": "30 Jun 2026 08:40", "sentiment": "positive", "sentiment_pct": 82, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artivion: PMA Approval Supports Accelerating Growth And Margin Expansion (NYSE:AORT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOVk04WEpqMEVnYVNtblZZWmlnbDNmVHRhV1BjS01KUEJaUEtybWI4ZUpwSmJ2WVBpNDUtN2tPTXZJdjRxYUpmQUd4RHVieTBiUG1mOTRpdzU1WmxFMDlPVHJVcG5tcWdGZzZRMnhhY3hWaDFDeE9hSjN3MVZBMEFFQk9oVmwta3gxN0EzZnZlcDBFU2hVajZCNjdraVM5aTg0QjVpY1hDVzRvQllBZlFkeDU2Ym45bHVaNmc?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 95, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Artivion, Inc. \u2013 SWB:CYL", "summary": "This article provides financial information for Artivion, Inc. (SWB:CYL) on the Stuttgart Stock Exchange. It specifically highlights the enterprise value to revenue forward metric for the company. The content appears to be a financial data point or a brief note from a financial p", "url": "https://www.tradingview.com/symbols/SWB-CYL/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T00:09:48", "published_display": "30 Jun 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artivion Seeks To Tap $150 Million US Market Opportunity With FDA Approval", "summary": "Artivion Inc. received FDA approval for its AMDS Hybrid Prosthesis, which treats acute DeBakey Type I aortic dissections, removing previous institutional review board requirements and easing access for hospitals. This approval validates clinical benefits observed in the PERSEVERE", "url": "https://www.sahmcapital.com/news/content/artivion-seeks-to-tap-150-million-us-market-opportunity-with-fda-approval-2026-06-29", "source_name": "Sahm", "published_at": "2026-06-29T21:41:47", "published_display": "29 Jun 2026 21:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AORT - Artivion Inc Options", "summary": "This article provides an overview of Artivion Inc. (AORT) stock options, displaying key financial metrics and performance indicators as of June 30, 2026. It includes data on market capitalization, earnings, sales, insider and institutional ownership, and various price performance", "url": "https://finviz.com/stock?t=AORT&ta=1&p=m&ty=oc&b=2&r=y5&ov=list_strike&s=12.5", "source_name": "Finviz", "published_at": "2026-06-29T20:10:13", "published_display": "29 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Artivion (AORT) Is Up 17.3% After Full FDA PMA Approval for AMDS Hybrid Prosthesis", "summary": "Artivion (AORT) shares rose 17.3% after receiving full FDA premarket approval for its AMDS Hybrid Prosthesis for acute DeBakey Type I aortic dissections, eliminating the need for prior hospital IRB approval. This approval validates the device's trial data, which showed significan", "url": "https://simplywall.st/stocks/us/healthcare/nyse-aort/artivion/news/why-artivion-aort-is-up-173-after-full-fda-pma-approval-for", "source_name": "Simply Wall Street", "published_at": "2026-06-29T17:40:53", "published_display": "29 Jun 2026 17:40", "sentiment": "positive", "sentiment_pct": 81, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artivion Wins FDA Nod for AMDS Hybrid Prosthesis", "summary": "Artivion has received U.S. FDA approval for its AMDS Hybrid Prosthesis, designed to treat acute DeBakey Type I aortic dissections. This device is the first aortic arch remodeling device for this condition and has shown significant reductions in mortality and major adverse events ", "url": "https://www.mpo-mag.com/breaking-news/artivion-wins-fda-nod-for-amds-hybrid-prosthesis/", "source_name": "Medical Product Outsourcing", "published_at": "2026-06-29T14:40:53", "published_display": "29 Jun 2026 14:40", "sentiment": "positive", "sentiment_pct": 95, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artivion Shares Rise After FDA Approves AMDS Aortic Device", "summary": "Artivion Inc. (NYSE: AORT) saw its shares rise after the FDA approved its AMDS Hybrid Prosthesis for treating acute DeBakey Type I aortic dissections, particularly those involving malperfusion. This approval removes the need for institutional review board authorization, broadenin", "url": "https://www.tradingpedia.com/2026/06/29/artivion-shares-rise-after-fda-approves-amds-aortic-device/", "source_name": "TradingPedia", "published_at": "2026-06-29T14:40:53", "published_display": "29 Jun 2026 14:40", "sentiment": "positive", "sentiment_pct": 87, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artivion, Inc.(NYSE: AORT) dropped from Russell Microcap Value Benchmark Index", "summary": "Artivion, Inc. (NYSE: AORT), a medical device company specializing in aortic diseases, has been removed from the Russell Microcap Value Benchmark Index. This news follows several other recent index removals for Artivion from benchmarks such as the Russell 2000 Defensive Index, Ru", "url": "https://www.marketscreener.com/news/artivion-inc-nyse-aort-dropped-from-russell-microcap-value-benchmark-index-ce7f5fded08cfe25", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T12:40:53", "published_display": "29 Jun 2026 12:40", "sentiment": "negative", "sentiment_pct": 27, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artivion receives FDA PMA approval for AMDS Hybrid Prosthesis in aortic dissections", "summary": "Artivion (NYSE:AORT) has received U.S. FDA premarket approval for its AMDS Hybrid Prosthesis, designed to treat acute DeBakey Type I aortic dissections with malperfusion. This approval eliminates HDE-related institutional review board requirements and is supported by data from th", "url": "https://grafa.com/en/news/united-states/artivion-fda-pma-approval-amds-hybrid-prosthesis-aortic-dissection", "source_name": "grafa.com", "published_at": "2026-06-29T11:59:00", "published_display": "29 Jun 2026 11:59", "sentiment": "positive", "sentiment_pct": 91, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artivion Announces U.S. FDA Approval of the AMDS Hybrid Prosthesis", "summary": "Artivion, Inc. announced that the U.S. FDA has approved the premarket approval application (PMA) for its AMDS Hybrid Prosthesis, a device for treating acute DeBakey Type I aortic dissections. This approval removes the previous requirement for hospitals to obtain IRB approval, fac", "url": "https://www.prnewswire.com/news-releases/artivion-announces-us-fda-approval-of-the-amds-hybrid-prosthesis-302812309.html", "source_name": "PR Newswire", "published_at": "2026-06-29T10:40:53", "published_display": "29 Jun 2026 10:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artivion receives FDA approval for aortic dissection device", "summary": "Artivion, Inc. (NYSE: AORT) has received FDA approval for its AMDS Hybrid Prosthesis, a device designed to treat acute DeBakey Type I aortic dissections, particularly those with clinical or radiographic malperfusion. This approval, based on positive data from the PERSEVERE U.S. I", "url": "https://www.investing.com/news/company-news/artivion-receives-fda-approval-for-aortic-dissection-device-93CH-4764985", "source_name": "Investing.com", "published_at": "2026-06-29T07:20:00", "published_display": "29 Jun 2026 07:20", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Artivion, Inc. \u2013 NYSE:AORT", "summary": "This page provides financial data for Artivion, Inc. (NYSE: AORT), specifically focusing on its forward price-to-earnings ratio. The content is presented within the TradingView platform, offering an overview of the company's financials for investors and traders.", "url": "https://www.tradingview.com/symbols/NYSE-AORT/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T20:40:08", "published_display": "28 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artivion, Inc. Actuals & Estimates (NYSE:AORT)", "summary": "This article provides an overview of Artivion, Inc. (AORT) stock, including its current price, market capitalization, and historical performance. It also details analyst forecasts, upcoming earnings reports, and financial metrics such as revenue, net income, and EBITDA, while cla", "url": "https://www.tradingview.com/symbols/NYSE-AORT/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T05:10:02", "published_display": "26 Jun 2026 05:10", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AORT Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Artivion, Inc. (AORT) stock, including analyst price targets, historical performance, and key financial metrics. According to 8 analysts, AORT has a max price estimate of $48.00 and a min estimate of $36.00. The article also details the compan", "url": "https://www.tradingview.com/symbols/NYSE-AORT/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T19:10:40", "published_display": "25 Jun 2026 19:10", "sentiment": "positive", "sentiment_pct": 59, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artivion Inc (AORT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a detailed revenue breakdown for Artivion Inc (AORT), showing its performance by business segment and geographical region. As of the latest update (Mon, Apr 6), the company's major revenue contributors are Aortic stent grafts, On X, and Preservation Services", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-aort/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T09:40:31", "published_display": "18 Jun 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artivion\u2019s Andrew Green sells $910,738 in company stock", "summary": "Andrew M. Green, SVP of Regulatory and Quality at Artivion (NASDAQ:AORT), sold company common stock totaling $910,738 on June 11, 2026. These transactions, executed under a Rule 10b5-1 trading plan, involved 44,001 shares at weighted average prices between $20.694 and $20.707. Pr", "url": "https://www.investing.com/news/insider-trading-news/artivions-andrew-green-sells-910738-in-company-stock-93CH-4742703", "source_name": "Investing.com", "published_at": "2026-06-16T14:40:31", "published_display": "16 Jun 2026 14:40", "sentiment": "negative", "sentiment_pct": 41, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artivion\u2019s Andrew Green sells $910,738 in company stock By Investing.com", "summary": "Andrew M. Green, SVP of Regulatory and Quality at Artivion (NASDAQ:AORT), sold 44,001 shares of company stock for $910,738 on June 11, 2026, under a Rule 10b5-1 trading plan. This sale occurred after he acquired the same number of shares through stock option exercises for $589,07", "url": "https://m.in.investing.com/news/insider-trading-news/artivions-andrew-green-sells-910738-in-company-stock-93CH-5455231?ampMode=1", "source_name": "Investing.com India", "published_at": "2026-06-15T16:40:12", "published_display": "15 Jun 2026 16:40", "sentiment": "negative", "sentiment_pct": 40, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artivion Insider Sold Shares Worth $910,739, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/artivion-insider-sold-shares-worth-153637872.html", "source_name": "MT Newswires", "published_at": "2026-06-15T15:36:37+00:00", "published_display": "15 Jun 2026 15:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artivion (AORT) SVP exercises options and sells 44,001 shares under 10b5-1 plan", "summary": "Artivion, Inc. (AORT) Senior Vice President Andrew M. Green executed a pre-arranged transaction under a Rule 10b5-1 trading plan, exercising stock options for 44,001 shares and subsequently selling all of these shares in open-market transactions. The sales occurred on June 11, 20", "url": "https://www.stocktitan.net/sec-filings/AORT/form-4-artivion-inc-insider-trading-activity-b328cd4db715.html", "source_name": "Stock Titan", "published_at": "2026-06-15T15:40:11", "published_display": "15 Jun 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precision Trading with Artivion Inc Com (AORT) Risk Zones", "summary": "This article analyzes Artivion Inc Com (AORT) with a focus on risk zones and trading strategies developed by AI models. It identifies a near-term neutral sentiment but suggests weakness in the mid and long term, highlighting elevated downside risk. The article provides specific s", "url": "https://news.stocktradersdaily.com/news_release/1/Precision_Trading_with_Artivion_Inc_Com_AORT_Risk_Zones_061326063202_1781389922.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-13T18:32:00", "published_display": "13 Jun 2026 18:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Artivion (AORT)'s Strong Q1 Growth But Lowered Guidance Means For Shareholders", "summary": "Artivion (AORT) reported strong 17.5% year-over-year revenue growth in Q1 2026 to US$116.3 million but missed analyst EPS estimates and slightly reduced its full-year guidance. This mixed performance highlights the company's growth momentum alongside challenges in profitability a", "url": "https://finance.yahoo.com/markets/stocks/articles/artivion-aort-strong-q1-growth-081650954.html", "source_name": "Market source", "published_at": "2026-06-12T08:10:28", "published_display": "12 Jun 2026 08:10", "sentiment": "negative", "sentiment_pct": 41, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] ARTIVION, INC. SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxQS0pKT2h4U3JZQ1RrblJiS01NbG53elFOY0xSNlMwQXc3VFBaRDMyOXZpT3VTQThVWlM1bUo0Skd6akdvVUZYbWhhUXpGaXZPV1gxdWltV3paS2xxazVQN2ZjeFF4aHZaTUtrWmcxTXczaEdKLWdmYjZoUW5XdGtaaHd2aWJYdW03WlJHWlNFVDY0cDg?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artivion (AORT) Q1 2026 Earnings: Revenue Growth of 17.5% Meets Expectations Amid Mixed Industry Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxPNVFJS3lud1FKdVE1UXdhNjNzQUM1OTgxZGtpYjFCaG43Zk5TOFUxU1AxalFmZHZHUmk5TUpwbnEzdndwYmstRU9yVXZCRjBkVXNWdXZjaXpwbjRJQ1dwNkNwZC01VFBja1R0RkJlQlZ4N2N0dTltUDMtUlJMWjBHd0FLUmpOcXpWS3gyVEFNUEt6ZzB5QU13SF8wWnZJLTZRem1SdXdBWlFpM01IZTNuZWtVcDhDeWNIN2RYajVJdmdsRmMtaGFqYg?oc=5", "source_name": "IndexBox", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Outperformers: Artivion (NYSE:AORT) And The Rest Of The Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQWlEweko5d2hyZUFhUjRsYU1QcElacmR0UktDcFZGUmFXSHpGN05OLV9tYS1VRTlfTHpGRXEzNi12cXZlcTJYVDhZRTZnWG1DUEVFT3hxMG5RcUpORUsyQWN3VVY0eENoZnFMYkdLOXk1Y2d5SFluWDBZU2ZsUl90cHZWY2pKQXZwS212WkcxejJjQ3hlYmtqMFRhWm1neHVYRDZvUzFtVmM4dXVY?oc=5", "source_name": "Market source", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artivion (NYSE:AORT) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxQcFVzS0xkWUdmUDQydWdoT2U2aF9DRkR0LUtWajA1MUZyMVlTbEJBR0h0S0FTN1ozY3k1SnlhMXB6WTZNRU95NVpScHNCVE5PRDRhX1IxcTFBenI1ZDdtRkdlN0t5azQ3eE1KLWYyWExfenF6TVN5bjBWUFFwUU1aczJvRk9mUDBzSjZEa1dlMW9VVUxQMFdxSGxZdHp1SHc?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artivion to acquire Israeli medtech firm Endospan in deal worth up to $335 million", "summary": "", "url": "https://news.google.com/rss/articles/CBMiaEFVX3lxTFB2M0NPTTV0WVhBeVR1MmZCT3dyVl81aHF5ZHZIMkRyV05pV3hCc0VwNkgtaEcxa2lmZWlJUzFyTS00NHhQZ0RSNXFIaXFtVGg0Uk5pZmRPNFZrMGE0cWdTZUhmaUw5VnJr?oc=5", "source_name": "calcalistech.com", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artivion Stock Dips 28% In One Day, Now Is Not The Time To Buy The Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxOZDdPZHJ3SUNQTzJvbUtuYUpZVHJMaHdHN3I2UVhFakYxTGt1UmxXcDlVUDNJckNubHhFRmVkT09fbTk3LWVhOUNsRDdBWHJYOWtvMHU0TE81ck5ISlIxcGZ4RFduOWZ6d191WmYyRHEwTmZYcnBMb2hvcTdHd09WR2hZVnUyb3BwZVphWkswWi05ZjVzMDNISXI0TDJqTDZyLUF4d2RFYmxIQ2tRM0k1N0x6WEY4Nk50cjU5bm5oNDd3aTFSbUpzYkNmZnAwX3RoM2VlVGw3Zw?oc=5", "source_name": "Trefis", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is Artivion stock plummeting today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOb3Y4ckVPVjFBXzZUNTJ4Nkt2LVVVY1ZKSUo1cF96UlhzaG1Gc2pydHYxY3lDajdOY25kMUFyb0EzbnhfNkVQXzNhWEg1NVA1cmVodlR5aUstTUxaX0V0OFR6amJ1NHRUWVZGNmYxb0t4cUh4YzUweV9zalBYckxZcnNOTTY1cHpvczlEWUYyTWNiRkVQYjJVUWNVVjNjQ1Z3UXc?oc=5", "source_name": "Investing.com", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Artivion (AORT) Stock Is Falling Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNQXRXbmhpcTJZZDNFSEo0WU9rNmhWcWdaTEZxYlpVRlNicmhvOFEzU3pwWC1rbHNFVWNJUDZuYnpzN0pwNVREVEFNSndaWWJoRGhRNW44UTA4M05rNHBZeHUtM0lKMkJvTm96TnNTR3RYa3lOWWNvQllSTzliYlZyNHlpal9KZ2ItMFJ5aWc5aDZ3NFVFbnJkVllIdUFVTUNFQkE?oc=5", "source_name": "StockStory", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artivion Reports First Quarter 2026 Financial Results and Announces Exercise of Option to Acquire Endospan", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9AFBVV95cUxPR3NQT00xOU91TkJWRktPVUZOYlQxV1FwclVJVEl0cWRDRU9TUHl4WmJsNEJheUdfWkY4U3k2NW5NSjktdURYamRTYk1HNzlaX0RTYy1YeUcxNU9EYkRBT3QtT0RWVmJPWi1NVWExMDF2bVhZbnN2T1Z3cXdvczFkNUJOTUNvRmQ2WFVIVGtGMEdNT2Q2aGVjN1ZuSGNhUGpfR0VuVzkwMGtWeEhFLTd6S3RJSUlkbER2aVlsRlJTcDB1c3pJeThrNVc0My1uRXNtdVo4YkFhYldJWUxvU1VPckpXZXRZMldPNlJhNmxtM1lPcDRB?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artivion (AORT) Q1 Earnings and Revenues Surpass Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQVU9JNFVrOUo0T1N1NEV2VHFSNm5IeFEyU1Z4aUdzNS1CbFE4TnVzX0k0US1ReDFWeE1qejlVcUFCcU9pVEJGWjI1aUFtdVMtb3FvLTZ6Y2M5Z01Sd1N1VTExRlN3VEZjbjBLTjZDekdHRUxIM2tRbnktNF9fQlR0TTdrQ2JLZjM2djdPN1d5ci1Jd3RObURmSlhrSEVIOFRr?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artivion (AORT) Soars 5.3%: Is Further Upside Left in the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxOelZodXlrMW5BMXZZNDdVenE1RE14Wlp0QUdWM3p0MWU3c1FDRXE3RjZnemhWaDhKWUV3WC1jMnFJbUdSQjVzX1lWc0ppc2xWMVNRWTNQRmFRVUhROGN1NkdFQTFscmV0RlpVeHBHWlRub1lGenFsMHRpRWFPa09nY1FTLUJWWFFOT0E5T3RnU1NuZw?oc=5", "source_name": "Market source", "published_at": "2026-04-08T07:00:00+00:00", "published_display": "08 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artivion Announces U.S. FDA Approval of the NEXUS\u00ae Aortic Arch System", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOUF9CTFg1VUo4R0E3UFBockdCZWI0Qi1XWF9vV2p5YVktanRRSU1TazlBdFhPSzFKbjFYTVZqNUk3a29OdGpkTm1xY0toU0x6TTUyZjMtSkZnTU51N1ZUOXdoNnNEbl8tQW1neG5TZnlKT3hGTE05WnJVSDJuSXp2dWFickl4MkxZMm9ZUDR0bXBLU1NxZHJsWFN6OXhIWDEzcG1VbnRWNmIwQnJrRG1zSVYxbV9YV1FIeFNwNmZobw?oc=5", "source_name": "PR Newswire", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Artivion (AORT) Stock Is Down Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxOZk9qVWoxaWFWT0daTkVOSEhyNVhrTnFyYmJPZ1RLU2FoNGl5RS1FazNQeVlnNDFlTS1mUVpBUWwwcGRManRDNWd5MmhoSFp4RWM5bGVMdHF6dkRSREo2d0cxR05JZUg1T21BZDF5Vzh6S1JFaTg4SWVTZDJHTmJxUXdVcmIxczhvSDlRUkYxdHhkRDlBeVpieQ?oc=5", "source_name": "Market source", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Artivion (NYSE:AORT) Vs The Rest Of The Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPaTgxS3dlMlZ5dDZ3dFlGdG9yRWFubkVqMk9yOTN6OEtyemljTWJGYUcxb2pmd2FTNTFKMlhIVGxrdlJsOG5iY1VQaXE4ZmYycTVpRkE0aEJ3QlB5bC10ZXN2dTFYNy0wRWdrNURVUlo5dEMzQklxQ0kwQTRkOXE0UDdTMkRGRWxoQ1ZQeG4tOXNONlR2SkxfZW5ST1B6N3BBeFZZQ3N1UFE?oc=5", "source_name": "Market source", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We Think Artivion's (NYSE:AORT) Profit Is Only A Baseline For What They Can Achieve", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-19T08:00:00+00:00", "published_display": "19 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Artivion (AORT) Is Down 7.6% After Mixed Q4 Results And 2026 Guidance Above Consensus", "summary": "", "url": "https://news.google.com/rss/articles/CBMiekFVX3lxTE1CR3J2NGNNTmRVRV9RRmFia1BiVjhKN2ZRcHNfakY0OXd2VldycVVlR2dGaDlmcTZfMUd5eVYwal81Wm01OWlOZEtGdU5SdHZMYVhfX0tRaG1YMHRGT2o2YVR4UTB5eWdtN0hNRG8zaGJIOUZKQXRmMjVR?oc=5", "source_name": "Market source", "published_at": "2026-02-13T08:00:00+00:00", "published_display": "13 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artivion (AORT) Stock Trades Down, Here Is Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxOUkF3ZmF5aWE2QXp5NXNBWUxILTROSnZadmVicDEybndvVHdkMkt1RWtQVVA5QU5XdVdxQW5yZ3JXeUQ4V3F5UHhPOFFKZGNPRGxSLXRBak93ZFpoLXd1cUhEdUxZVVA2UXRmWlgzWi1xVTFEME1uQVNHcllpcngzdk1Ddw?oc=5", "source_name": "Market source", "published_at": "2026-02-13T08:00:00+00:00", "published_display": "13 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Artivion Reports Fourth Quarter and Full Year 2025 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxOczFDeHJMOU1jbFFTNXR1SE1lZmdrUU1PZ3BFUmFteFJFRng3RHAzMU5QS3ZWQzhLVklyVElpWlBqM1phVVNIMGhBRGtrMXRZUXJiNm1zNW15bVBwOXByc2ZydkZkUC1EQzE3eEJPUXBVTkY0YVFLb290eGoyWTZUX09UMnNsTUg2ZlJuUk13MVFhWDZPeDRKdWVEWXhyc3JoUVlfMFVSWU5yQmJpLThZY0ZqZFpFMDdIZXJyelFRWUdPQQ?oc=5", "source_name": "PR Newswire", "published_at": "2026-02-12T08:00:00+00:00", "published_display": "12 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Reflecting On Medical Devices & Supplies - Specialty Stocks\u2019 Q1 Earnings: Integer Holdings (NYSE:ITGR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNUFd1SUpRcWlCdEFjU1YzNTZkdjBfRkwyY2lBYjh1ZXZlZTlyVlpWSWx1bExvckFrNHNhUEdVTGNFWUxaMkVDZUV2c2hPS1h2YVhNSHNsVzFYNUFrNHBnRVM1STRsa2Zmb0VXeEQ4UFRGNDBOWXZfWVU5VFUyQ3JZZm9KamZMWXVDSEtNMWwyVktpaEZfRjVNU1BYaWJ3NnpNUmRyMEpsSzBXdw?oc=5", "source_name": "Market source", "published_at": "2026-07-14T18:07:11+00:00", "published_display": "14 Jul 2026 18:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks Q1 Earnings: ICU Medical (NASDAQ:ICUI) Firing on All Cylinders", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAJBVV95cUxQLWl0NWl5MFJhUXFSN0pzSW1sVzJVb21XVml0X0doQnd5eDVUQmVqeFZWSmNmdlZaV2pfbFk3UEl3RXlqZ05pckozR0dnNHNEUlpTa2FPYWc1Z3Q0Y2tXYTljZUlQRkVZNzY2Sl9yRksyUDJkNVQzSTBuLW9uMnI5bzBfTTJGdDUzd25DN3dDSmhwWnpGVXZRVVM2Uy1zMnp4STZ1RGdZZkRpZ21Pb2xtWjRSTk1kc2JrT28wTG81NDV1M2tWaVdrOXBQdVZSTExiTVEzMXpqRnJWWi0xcEdMYVFILXZXbXZVZl9GRm12aTl5OGk4X1dSVjVyU2FIVFpubk1YNm5fQll0MVZqRTZpTA?oc=5", "source_name": "StockStory", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q1 Earnings Review: Medical Devices & Supplies - Diversified Stocks Led by Baxter (NYSE:BAX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNYjhBT3BjMWFVU1FFUUFub0d6QUVEUTdwWFVMRG5fN2dHSnIxTXQwMWU1aElKaEV1a2dYLTFHMlBzMVFTZEtaX0xRRDFhZDl1WFdDYWF2RDZxOG9SRUtycmZacTRzM2FaaEU3OS1GZ2taLWtSMjZ4enhVNHRvdzJsanp4cEhNcGI1dllTOUplWUUtNjRlRm85MlFEVWxSYUV2d243QVd3?oc=5", "source_name": "Market source", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Medical Devices & Supplies - Specialty Q4 Earnings: Globus Medical (NYSE:GMED) is the Best in the Biz", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNcDFMNmtOVk5PVFM1YzMyVWhyS3dwY0dMVE5BUng5U1JoOFRQMXNFRGxTMmlBRUV0bENRSWFXTDFZOXBQQkNZT0FOWDdISjRCcU9pRV9aNHBwUVBuZkVEV3g1dklVY19KOE9iWUNpNUtMS2NuOEcxMlQtNU8ydURybEdkNVoxZThWLTBIeVhid2NjQ0FWWTUzb2dxcmlMQThFQmZ4bldzRjcwUQ?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Medical Devices & Supplies - Imaging, Diagnostics Stocks\u2019 Q4 Earnings: Hologic (NASDAQ:HOLX) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOdkl6Ym5HSGVhZUw3TzNlNVFPSjdDQk5NMTVSRW1xVnh3RE5RNU9veVR0TDEtcVdxV3BYelI0bWxCYXgwWmhZQ3ZONUVRdlhjX0ZiMklRVDJQRXN0LXcyVWVnb0E2WTdiRERtZk1pNGpmVHhWbHl5eHJuNnBtTDVPMUluTmRsQUVqYjNlSl8zR3djclh0X2ZIc1gzTlhPanR6ZTJ6R1FB?oc=5", "source_name": "Market source", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: CooperCompanies (NASDAQ:COO) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOellVLTAtRXF1dTFacmVLUmptUVpDSkxGX0MtY2hCY2l3ajU4M25SMG95OHdlc1RHN1dmaHZZMF9uQ0o3R1FBa0NzQUtZMjIzMjU1bmttbGZsZUplQkd5Vmd2NEJoQ0NnbVhmVXppdWhiQkdpcGpQVFJVSHRBXy1pbnFJbXI0R2w3MmlvMEdCY2dGYVE4cWY2MENmeEp1ME9mZEFqSDVtdThTMk9kbUhIdXMtR0k?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q4 Earnings: Integer Holdings (NYSE:ITGR) In The Context Of Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAJBVV95cUxNdFRrRlJvM3J3cGJnVEJ6ZndqMnQxWkE4Wm8zTGtPTVc0OTlLN1pwNXIyclNJMFZkcG5qQTRTWThmNm9WN0hKYXBja3N3Y20zSlkxc2JaQlpYTnAyWnpvUVBvR1JWNmVxZGhSYVlYQklMd01GeFBVNGJWOFBWYUkwYmRrM2xrSktiQWpfTkZtNG1HWThNT0tqLUpYek5qcnFWMGE0QV9CaElrMUpfTEhnOC1pS2t1bkE2VVJHdEhWdEtoX2xKNE1MWk1OSlBSNTVZVU83WEpnb3E4aURwQ3ZyZUFDbndpTTZEa0lZRTJvU2VuTDhreXdCQ25iV3Y4YWxENm1xYQ?oc=5", "source_name": "StockStory", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highs And Lows: Abbott Laboratories (NYSE:ABT) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPeVpVN2I3X3lJNXd3TXJmRWV4X0RvRDdYR3l5a1k1SjMxUlhsWHdrUUNuZ1JIaUg4czdhZlA2VDVIallROFFuNmZXcnNzS1d3Vm0wS0tLMmlFVWdkUThsRDZYdTdZV3k3WkRjaUZSMUQ3dkRKYm5ZOVBjMVVBdTRjYQ?oc=5", "source_name": "Market source", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q4 Earnings: Enovis (NYSE:ENOV) In The Context Of Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNMzBPcXU1cnZKekZnaGlNVk05ZWFTWThNOS0tTlpvQjdaLVZIWlVXUk50NnVoQ0pPWWJpZUpWcVJyVDJMd2RJREVDbEEzTlU5UGhBbWtxWVEyVkdaMTVuNXZpaWFMNTZUQ2d0OW9Rc29kalJRY21naWlHZDBLS3RuZV9wdTdIUQ?oc=5", "source_name": "Market source", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highs And Lows: Baxter (NYSE:BAX) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxOb3BiQVNFREdNblk2QS10b1lhRUtfb05vU2VFZHB5V0hJT0R4NmhwQWRrcFVsR3UwMjZleFV6N2FEelpZVzY3YWFxSWE1cWpLaTFrQVU4NktkQUloUkxaV3ZTVkh6b1ZmaDdMN2ViX1BUNE4xUTNUZFNlR0syVGlZSg?oc=5", "source_name": "Market source", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 97, "total_relevant": 59, "sentiment_summary": {"positive": 20, "negative": 4, "neutral": 35, "score": 60, "total": 59, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "earnings", "primary_label": "Earnings", "confidence": 76, "events": [{"event": "earnings", "label": "Earnings", "weight": 14.38, "count": 28}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 9.35, "count": 17}, {"event": "general", "label": "Market update", "weight": 6.6, "count": 12}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 20, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 24.09, "latest_week": "2026-07-10", "one_week_move": 0.5, "four_week_move": 19.9, "twelve_week_move": -36.1, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.667773, "market_dynamics_buy_signal": false, "relative_strength": -42.095246, "fair_value_gap": -13.1, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 45.0046, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+0.5% over one week, +19.9% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 59, "badges": [], "opportunities": [], "risks": [], "event_label": "Earnings", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 18}, {"label": "TradingView", "count": 4}, {"label": "PR Newswire", "count": 4}, {"label": "Simply Wall Street", "count": 3}, {"label": "Stock Titan", "count": 3}, {"label": "Investing.com", "count": 3}, {"label": "StockStory", "count": 3}, {"label": "Moomoo", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 49}, {"label": "Industry context", "count": 10}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 28}, {"label": "Regulatory and legal", "count": 17}, {"label": "Market update", "count": 12}, {"label": "Analyst action", "count": 1}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "60/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Earnings", "tone": "neutral", "text": "76/100 classification confidence."}, {"label": "Company focus", "value": "49", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+0.5% over one week, +19.9% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Artivion (AORT) Corporate presentation Summary"}], "updated_at": "2026-07-17T10:59:59.619047+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}